Open Access

Association between CD4+ T cells ATP levels and disease progression in patients with non‑small cell lung cancer

  • Authors:
    • Weipeng Ye
    • Kailian Hou
    • Na Tao
    • Weiyi Li
    • Zhiqiong Tan
    • Qunfeng Huang
    • Dongheng Yang
    • Haoxin Lin
    • Zihao Deng
    • Yuanyuan Xia
    • Guifang Yu
  • View Affiliations

  • Published online on: June 12, 2024     https://doi.org/10.3892/ol.2024.14502
  • Article Number: 369
  • Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Introducing the exploration of stimulated CD4+ cells adenosine triphosphate (sATPCD4) levels for immune monitoring post non‑small cell lung cancer (NSCLC) chemotherapy, the present study aimed to investigate its efficacy in gauging the potential risk of disease progression (PD) in patients with NSCLC. Therefore, a total of 89 patients with advanced NSCLC, who underwent chemotherapy between August 15 2022 and August 30 2023 at the Fifth Affiliated Hospital of Guangzhou Medical University (Guangzhou, China), were retrospectively studied. Patients were divided into the PD (n=21) and disease stability (non‑PD; n=68) groups and their clinical data were compared. The thresholds for predicting PD were identified using receiver operating characteristics (ROC) curves. Multivariate logistic regression analysis was carried out to assess the association between peripheral blood markers and the incidence of PD. Therefore, post‑chemotherapy, significant differences in white blood cell count, non‑stimulated CD4+ cells ATP and sATPCD4 levels were obtained between patients in the PD and non‑PD groups (P<0.05). In addition, sATPCD4 levels were notably decreased in the PD group compared with the non‑PD group. Furthermore, ROC analysis revealed that the predictive threshold for PD was 224.5 ng/ml [area under the curve=0.887; 95% confidence interval, 0.811‑0.963]. Additionally, patients with low immunity (ATP <224.5 ng/ml) exhibited a higher risk of PD compared with the high‑immunity group (ATP >224.5 ng/ml; P<0.0001). Finally, multivariate logistic regression analysis suggested that sATPCD4 could serve as an independent factor for predicting NSCLC progression. Overall, the current study predicted that immune function could be possibly associated with the risk of PD in patients with NSCLC.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 28 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ye W, Hou K, Tao N, Li W, Tan Z, Huang Q, Yang D, Lin H, Deng Z, Xia Y, Xia Y, et al: Association between CD4<sup>+</sup> T cells ATP levels and disease progression in patients with non‑small cell lung cancer. Oncol Lett 28: 369, 2024.
APA
Ye, W., Hou, K., Tao, N., Li, W., Tan, Z., Huang, Q. ... Yu, G. (2024). Association between CD4<sup>+</sup> T cells ATP levels and disease progression in patients with non‑small cell lung cancer. Oncology Letters, 28, 369. https://doi.org/10.3892/ol.2024.14502
MLA
Ye, W., Hou, K., Tao, N., Li, W., Tan, Z., Huang, Q., Yang, D., Lin, H., Deng, Z., Xia, Y., Yu, G."Association between CD4<sup>+</sup> T cells ATP levels and disease progression in patients with non‑small cell lung cancer". Oncology Letters 28.2 (2024): 369.
Chicago
Ye, W., Hou, K., Tao, N., Li, W., Tan, Z., Huang, Q., Yang, D., Lin, H., Deng, Z., Xia, Y., Yu, G."Association between CD4<sup>+</sup> T cells ATP levels and disease progression in patients with non‑small cell lung cancer". Oncology Letters 28, no. 2 (2024): 369. https://doi.org/10.3892/ol.2024.14502